Lack of age and gender effects on single-dose pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem
- PMID: 19371322
- PMCID: PMC2679112
- DOI: 10.1111/j.1365-2125.2009.03367.x
Lack of age and gender effects on single-dose pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem
Abstract
Aims: To investigate the effect of age and gender on the tolerability, safety and pharmacokinetics (PK) of tomopenem (RO4908463/CS-023), a novel carbapenem antibiotic, and its major metabolite.
Methods: Forty-two subjects were assigned to one of the following three groups: young men, elderly men and elderly women. The PK, safety and tolerability of an intravenous infusion of 1500 mg tomopenem and its resultant major metabolite (open beta-lactam ring) were assessed.
Results: Minor differences in exposure of both tomopenem and the major metabolite were seen. The area under the curve (AUC) of tomopenem was 22% higher in elderly men compared with young men, and 19% higher in elderly women relative to the elderly men. Total clearance of tomopenem decreased with decreasing creatinine clearance. In the two male groups, renal clearance values of tomopenem were similar (3.52 and 3.67 l h(-1)) and higher than in the elderly female group (2.83 l h(-1)). The mean half-lives ranged from 2.03 (healthy young men) to 2.41 h (elderly men). The difference in AUC of tomopenem can be explained by differences in the mean creatinine clearances of 116 (young men), 101 (elderly men) and 84.7 (elderly women) ml min(-1) 1.73 m(-2), respectively.
Conclusions: While some PK parameters were statistically different among the three groups, the differences were mostly minor and unlikely to be clinically meaningful. The difference in the PK can be largely attributed to the difference in creatinine clearance of these groups.
Figures
Similar articles
-
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.Antimicrob Agents Chemother. 2008 Jul;52(7):2360-6. doi: 10.1128/AAC.01249-07. Epub 2008 Apr 28. Antimicrob Agents Chemother. 2008. PMID: 18443123 Free PMC article. Clinical Trial.
-
Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects.Antimicrob Agents Chemother. 1998 Jun;42(6):1433-6. doi: 10.1128/AAC.42.6.1433. Antimicrob Agents Chemother. 1998. PMID: 9624490 Free PMC article.
-
In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.J Antimicrob Chemother. 2008 Dec;62(6):1326-31. doi: 10.1093/jac/dkn411. Epub 2008 Oct 3. J Antimicrob Chemother. 2008. PMID: 18835805
-
Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.Antimicrob Agents Chemother. 2006 Dec;50(12):4186-8. doi: 10.1128/AAC.00494-06. Epub 2006 Oct 16. Antimicrob Agents Chemother. 2006. PMID: 17043123 Free PMC article.
-
Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010. Clin Ther. 2012. PMID: 23063375 Clinical Trial.
Cited by
-
Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection.Antimicrob Agents Chemother. 2011 Nov;55(11):5004-9. doi: 10.1128/AAC.00068-11. Epub 2011 Aug 15. Antimicrob Agents Chemother. 2011. PMID: 21844314 Free PMC article.
References
-
- Ohya S, Fukuoka T, Kawada H, Kubota M, Kitayama A, Abe T, Kuwahara S. 40th Intersci Conf Antimicrob Agents Chemother, abstr F-1232 R-115685, a novel parenteral carbapenem: in vivo antibacterial activity. Abstr 40th Intersci Conf Antimicrob Agents Chemother, abstr F-1232. 2000;40:205.
-
- Noel AR, Bowker KE, MacGowan AP. The RO4908463 (CS-023) T > MIC antibacterial effect relationship for MRSA established in an in vitro pharmacokinetic model of infection. Abstr 46th Intersci Conf Antimicrob Agents Chemother abstr A-638. 2006;46
-
- Thomson KS, Moland ES. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J Antimicrob Chemother. 2004;54:557–62. - PubMed
-
- Mouton JW, Touw DJ, Horrevorts AM, Vinks AATMM. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet. 2000;39:185–201. - PubMed
-
- Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999;45:243–53. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous